The test is designed for adults aged 40 and older who present with signs or symptoms of cognitive impairment and are undergoing clinical assessment. Its significance for laboratory medicine is not that it replaces clinical diagnosis, but that it introduces a validated blood-based alternative to PET imaging for assessing brain amyloid pathology.
The analytical architecture
PrecivityAD2 is built around simultaneous measurement of amyloid and tau proteins, the two biomarker classes central to the biological characterization of Alzheimer’s disease in the evidence provided. C2N Diagnostics reports that the assay uses high-resolution mass spectrometry for protein biomarker quantitation, rather than relying on a single analyte or an isolated signal.
Those measurements are integrated into a composite result called the Amyloid Probability Score 2, or APS2. The score is expressed as a whole number from 0 to 100 and evaluated against clinical cutoffs to indicate whether an individual is likely to have brain amyloid pathology.
That architecture matters because the assay is not presented as a generic cognitive-impairment panel. Its analytical purpose is narrower and more clinically defined: to detect evidence associated with amyloid plaque accumulation and use that result to support a broader assessment for Alzheimer’s disease. In molecular diagnostics terms, the value proposition rests on biomarker quantitation, multiplexed interpretation and a validated score that can be incorporated into clinical decision-making.
Clearance is not a standalone diagnosis
The FDA clearance applies to symptomatic adults aged 40 and older who are being evaluated for Alzheimer’s disease. The test is not intended to function as a standalone diagnostic, and it is not a screening tool. A clinical evaluation remains part of the intended pathway, with the blood test providing additional information for healthcare professionals assessing whether Alzheimer’s pathology is present.
This distinction is operationally important for laboratories and clinics. A result from PrecivityAD2 should be interpreted within the assay’s intended-use population and against the specified clinical cutoffs for APS2. The clearance therefore supports a defined use case rather than an unrestricted blood-based determination of Alzheimer’s disease in the general population.
Newsweek reports that the test is expected to become available later this year and that C2N Diagnostics describes it as the first FDA-cleared test for symptomatic adults aged 40 and older in this category. The available evidence does not establish that the assay eliminates the need for other laboratory tests, imaging or specialist assessment; it supports the more limited conclusion that blood-based biomarker data may provide an additional route for evaluating Alzheimer’s pathology.
What laboratories should monitor
For clinical laboratories, the immediate issue is implementation discipline rather than headline-level substitution of PET scans. The critical documents will be the cleared intended-use language, the assay’s validation framework, the analytical definition of APS2 and the clinical cutoffs used to classify results. Those elements determine how the test can be ordered, reported and incorporated into a patient’s diagnostic pathway.
The mass-spectrometry component also places the assay within a laboratory workflow that depends on quantitative protein biomarker measurement and controlled interpretation of a composite score. The relevant question for adopting sites will be how the test’s validated performance and reporting model align with existing clinical evaluation processes—not whether a blood result can independently establish disease.
PrecivityAD2 marks a meaningful shift in Alzheimer’s diagnostics toward blood-based molecular assessment, but its near-term impact will depend on disciplined deployment within the cleared population. The emerging paradigm is additive: a laboratory-generated biomarker result that can refine clinical assessment, potentially reducing dependence on more resource-intensive imaging in selected evaluations without converting molecular evidence into a standalone diagnosis.